Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome

PURPOSE: Glioblastoma (GBM) immunotherapy clinical trials are generally initiated after standard-of-care treatment, including surgical resection, perioperative high-dose steroid therapy, chemotherapy, and radiation treatment, has either begun or failed. However, the impact of these interventions on...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Otvos, Balint, Alban, Tyler J., Grabowski, Mathew M., Bayik, Defne, Mulkearns-Hubert, Erin E., Radivoyevitch, Tomas, Rabljenovic, Anja, Johnson, Sarah, Androjna, Charlie, Mohammadi, Alireza M., Barnett, Gene H., Ahluwalia, Manmeet S., Vogelbaum, Michael A., Fecci, Peter E., Lathia, Justin D.
Format: Artigo
Jezik:Inglês
Izdano: 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8026586/
https://ncbi.nlm.nih.gov/pubmed/33542075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3262
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items